Event

Connect with Quotient Sciences at the upcoming 14th Drug Delivery and Formulation Summit in Berlin from 31st May to 2nd June.

Schedule a meeting

News

Quotient Sciences Supports Crinetics Pharmaceuticals with Fully Integrated Pediatric Development and Clinical Testing Program

Crinetics Pharmaceuticals and Quotient Sciences announce a partnership to support Crinetics’ CRN04894 pediatric program.

Eleanor Row Discovery to IND SpeakPharma

Eleanor Row discusses the challenges and considerations that drug developers should be aware of when quickly advancing their molecules from discovery to the investigational new drug (IND) stage and onward into the clinic, while emphasizing the benefits of an integrated approach to accelerate the process.

3 Key Trends Shaping Our Industry: Contract Pharma Thought Leadership Feature with Eleanor Row

Quotient Sciences’ Executive Director of Commercial, Eleanor Row, offers her thought leadership in Contract Pharma on the 3 key trends shaping our industry.

Evecxia Therapeutics Reports Favorable Data From a Phase 1 SAD/MAD Trial

Quotient Sciences has supported Evecxia with the Phase 1 two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram. Favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data was announced from the study.

Quotient Sciences Announces Significant Growth in Workforce at Alnwick, UK, Facility

Quotient Sciences has grown the workforce at its Alnwick, UK, facility by 20% over the past 2 years.

Dr. Dolly Jacob: Solubility & Bioavailability

Dr. Dolly Jacob, Director of Integrated Development Services at Quotient Sciences featured in Drug Development & Delivery looking at the challenges of solubility & bioavailability.

Dr. Vanessa Zann: Pharmaceutical Technology Contribution

Dr. Vanessa Zann, Senior Drug Development Consultant at Quotient Sciences featured in Pharmaceutical Technology looking at the important role of early-phase biopharmaceutics.